AI Article Synopsis
- The study explores the historical use of sclerosing agents for treating venous diseases and the common side effect of hyperpigmentation, particularly examining whether elevated serum ferritin levels play a role in this condition.
- A patient with hemochromatosis and a very high serum ferritin level was treated for spider veins, but no noticeable hyperpigmentation appeared after six months of sclerotherapy.
- Histological analysis showed macrophagic pigmentation both before and after treatment, leading to the conclusion that there is no confirmed link between high serum ferritin levels and post-sclerotherapy pigmentation, indicating the need for further research on this topic.
Article Abstract
Background: Human beings have suffered and sought treatment for disease of veins as early as the recordings of the old testament. The use of irritating sclerosing agents have been and are widely used today to treat varicose veins and telangiectasia. One of the most common and cosmetically significant side effects of sclerosing agents is varying degrees of hyperpigmentation. It has been reported that elevated serum ferritin level plays a role in this postsclerotherapy pigmentation.
Objective: To support or negate the possibility of a direct correlation between serum ferritin levels and pigmentation postsclerotherapy using for our investigation a patient with hemochromatosis.
Methods: A patient with hemochromatosis having a serum ferritin level of 1200 was treated for spider veins. Clinical and histologic studies were performed pretreatment and posttreatment.
Results: There was no clinically apparent hyperpigmentation noted on the patient after sclerotherapy over a 6-month period. Histology reports revealed macrophagic pigmentation both pretreatment and posttreatment.
Conclusion: Our results do not confirm the theory that lab values of elevated serum ferritin correlate with pigmentation postsclerotherapy. Further study of the correlation between postsclerotic pigmentation and serum ferritin levels are needed. One would anticipate that if a true correlation existed, then an extreme case such as this would clearly support this theory.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pulmonary and serum cytokine profiles of patients with anti-ARS and anti-MDA5 antibodies.
J Autoimmun
January 2025
Department of Rheumatology, Dokkyo Medical University, Mibu, Tochigi, 321-0293, Japan.
The present study aimed to determine the pulmonary cytokine profiles of patients with anti-RNA synthetase (ARS) and anti-melanoma differentiation-associated protein 5 (MDA5) antibodies. The study included patients with ARS and MDA5 whose serum or bronchoalveolar fluid (BALF) was available. Sandwich enzyme-linked immunoassay microarray multiplex assay was used to measure 18 cytokine levels in serum and BALF.
View Article and Find Full Text PDFLysyl oxidase-like 2 promotes the survival, migration, and ferroptosis of endometrial cancer cells by activating the phosphoinositide 3-kinase/protein kinase B pathway.
Iran J Basic Med Sci
January 2025
Department of Obstetrics and Gynecology, Shanghai Pudong Hospital of Fudan University, Pudong, Shanghai-201399, China.
Objectives: LOXL2, known as Lysyl oxidase-like 2, is classified as a lysyl oxidase (LOX) family member. However, its role and mechanism in endometrial cancer (EC) are unknown. Therefore, we aimed to investigate the potential role and mechanism of LOXL2 in EC.
View Article and Find Full Text PDFRationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure.
Eur J Heart Fail
January 2025
Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Aims: While it is widely accepted that intravenous (IV) iron improves functional capacity, symptoms, and cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF) diagnosed with iron deficiency (ID), three recently published cardiovascular outcome trials (AFFIRM-AHF, IRONMAN and HEART-FID) of IV iron supplementation in HF failed to demonstrate a significant benefit on their respective primary endpoints. Dosing of IV iron after the initial correction of baseline ID - by design or as a result of trial circumstances - was relatively low (i.e.
View Article and Find Full Text PDFRunning Low: A Seasonal Analysis of Micronutrient Deficiencies on External-Load Measures in Elite Female Rugby League Players.
Int J Sports Physiol Perform
January 2025
Research Institute for Sport and Exercise (UCRISE), University of Canberra, Canberra, ACT, Australia.
Unlabelled: Iron and vitamin D are essential for physiological mechanisms underpinning physical capacities characterizing team-sport performance. Yet, the impact of iron deficiency on physical capacities beyond endurance is not clear.
Purpose: The purpose of this study was to assess variations in seasonal micronutrient concentrations and how iron deficiency impacts external-load measures in elite female rugby league players.
TLR7 responses in glomerular macrophages accelerate the progression of glomerulonephritis in NZBWF1 mice.
Int Immunol
January 2025
Division of Innate Immunity, The Institute of Medical Science, The University of Tokyo; Minato-ku, Tokyo 108-8639, Japan.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies and damage to multiple organs. Glomerulonephritis, a manifestation involving glomerular deposition of immune complexes and complement components, significantly contributes to disease morbidity. Although the endosomal single-stranded RNA sensor TLR7 is known to drive glomerulonephritis by promoting autoantibody production in B cells, the contribution of macrophage TLR7 responses to glomerulonephritis remains poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!